Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X about a paper by X. Lyu et al. published in ESMO Open:
“Not just KRAS and BRAF – FGFR1 joins the club of high-risk CRC alterations.
Study: ESMO Open | 7606 CRC cases (608 in-house + 6998 public)
Finding: FGFR1 amplification (3.8–4.3%) → dominant FGFR event in CRC
Prognostic hit:
- DFS: 13 vs 45 mo (HR 2.9)
- PFS: 16 vs 19 mo (HR 2.0)
- Effect size ≈ KRAS/BRAF mutations
Clinical translation:
- New IRS IHC scoring system = 95% concordance with NGS
- Enables cost-effective pathology-based screening
Take-home:
FGFR1 amplification = a distinct, aggressive CRC subtype – needs biomarker-driven stratification & novel targeted therapies.”
Title: FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
Authors: X. Lyu, R. Cai, B. Han, Y. Liu, Y. Zhang, Z. Wu, Y. Cheng, Z. Lin, G. Qin, X. Xie, J. Zhang, W. Zhan, Y. Deng
You can read the Full Article in ESMO Open.
More posts featuring Rishabh Jain.